Abstract
Introduction: Chronic Myeloid Leukemia is a type of malignant blood neoplasia that is mainly characterized by the presence of the Philadelphia chromosome that originates the oncoprotein BCR-ABL. It has increased tyrosine kinase activity, thus causing changes in intracellular signaling pathways and promoting uncontrolled proliferation, cellular dysfunction and absence of apoptosis. Despite the low incidence of the disease, 1.5 cases per 100,000 inhabitants, therapy with Imatinib, a potent inhibitor of BCR-ABL, changed the prognosis of the disease and extended the life expectancy of patients, transforming a fatal disease into a chronic condition. Objective: To develop a form for regular monitoring of these patients by the clinical pharmacist to ensure safe and effective pharmacotherapy. Methodology: Narrative-type literature review was initiated from the problem question: ‘“What data should be collected by the Clinical Pharmacist during pharmaceutical assistance to assess and improve adherence in adult patients with Chronic Myeloid Leukemia using Imatinib?” , followed by search for articles in PubMed databases and government websites. Subsequently, work selection and critical analysis were carried out to build a model form to be applied in the act of dispensing. Result and Discussion. Eleven articles were selected. The patient’s low adherence to the treatment of chronic myeloid leukemia can result in potentially life-threatening. Therefore, the follow-up form to be applied by the clinical pharmacist when dispensing imatinib mesylate is a viable and low-cost strategy to improve adherence to pharmacotherapy and promote a better response to treatment. Conclusion: The systematic and standardized documentation of adherence and adverse effects by the Clinical pharmacist allows the implementation of actions by the multidisciplinary team of continuous improvements in order to maximize the quality of care provided to patients as well as the quality of life.
Highlights
Cancer is the name given to a set of more than one hundred pathologies, which has as common characteristics the initiation by damage in specific DNA genes and the autonomous and disordered growth of cells that acquire the ability to invade adjacent organs and tissues resulting in functional disorders (THAVAMANI et al, 2014).This abnormal cell proliferation is known as neoplasia and in practice it is called tumor, and can be classified as malignant or benign (INSTITUTO NACIONAL DO CÂNCER, 2019).A special group of malignant neoplasms are leukemias, which are characterized by abnormal proliferation of bone marrow cells precursors of the white lineage (JULIUSSON And HOUGH, 2016; LIU et al, 2019)
Chronic Myeloid Leukemia (CML) is a type of blood disorder characterized by an increase in the number of leukocytes with left deviation, splenomegaly and the presence of the www.nucleodoconhecimento.com.br
From the problem question: “What data should be collected by the Clinical Pharmacist during pharmaceutical assistance to evaluate and improve the adherence of adult patients with Chronic Myeloid Leukemia using Imatinib?” a search was carried out on the PubMed platform based on the PICO strategy and the descriptors were used: “leukemia, myelogenous, chronic, bcr-abl positive” AND “adherence medication”
Summary
Cancer is the name given to a set of more than one hundred pathologies, which has as common characteristics the initiation by damage in specific DNA genes and the autonomous and disordered growth of cells that acquire the ability to invade adjacent organs and tissues resulting in functional disorders (THAVAMANI et al, 2014).This abnormal cell proliferation is known as neoplasia and in practice it is called tumor, and can be classified as malignant or benign (INSTITUTO NACIONAL DO CÂNCER, 2019).A special group of malignant neoplasms are leukemias, which are characterized by abnormal proliferation of bone marrow cells precursors of the white lineage (JULIUSSON And HOUGH, 2016; LIU et al, 2019). Cancer is the name given to a set of more than one hundred pathologies, which has as common characteristics the initiation by damage in specific DNA genes and the autonomous and disordered growth of cells that acquire the ability to invade adjacent organs and tissues resulting in functional disorders (THAVAMANI et al, 2014). This abnormal cell proliferation is known as neoplasia and in practice it is called tumor, and can be classified as malignant or benign (INSTITUTO NACIONAL DO CÂNCER, 2019). Philadelphia chromosome (Ph), which results from reciprocal translocation between chromosomes (9;22) (q34;q11), giving rise to bcr-abl protein, with increased tyrosine kinase activity (FLIS And CHOJNACKI, 2019).
Sign-in/Register to view highlights & summary Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callMore From: Revista Científica Multidisciplinar Núcleo do Conhecimento
Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
